Cost of Revenue Trends: Exelixis, Inc. vs Travere Therapeutics, Inc.

Biotech Cost Trends: Exelixis vs. Travere

__timestampExelixis, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 20142043000570979
Thursday, January 1, 201538950002185000
Friday, January 1, 201665520004554000
Sunday, January 1, 2017150660003605000
Monday, January 1, 2018263480005527000
Tuesday, January 1, 2019330970005234000
Wednesday, January 1, 2020362720006126000
Friday, January 1, 2021528730006784000
Saturday, January 1, 2022579090007592000
Sunday, January 1, 20237254700011450000
Loading chart...

Cracking the code

Cost of Revenue Trends: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart provides a fascinating glimpse into the cost of revenue trends for Exelixis, Inc. and Travere Therapeutics, Inc. over the past decade. From 2014 to 2023, Exelixis, Inc. has seen a staggering increase in its cost of revenue, growing by over 3,400%, from approximately $2 million to $72 million. In contrast, Travere Therapeutics, Inc. experienced a more modest growth of around 1,900%, starting at $570,979 and reaching $11 million. This divergence highlights the varying operational scales and strategic investments of these companies. As Exelixis, Inc. continues to expand its market presence, Travere Therapeutics, Inc. is steadily increasing its cost efficiency. These trends offer valuable insights into the financial health and strategic directions of these biotech firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025